Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Slideshows|January 26, 2017
7 Components of Depression Evaluation
Author(s)Guy G. Potter, PhD, David C. Steffens, MD
The co-occurrence of depression and cognitive impairment doubles every 5 years after the age of 70. Here we present a list of elements in a comprehensive and extended evaluation of depression in the elderly.
Advertisement
Advertisement
Related to this article
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
3
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5